Precision BioSciences, Inc. Common Stock

Day range

$6.38 – $6.88

Open

$6.68

Prev close

$6.64

Volume

124.67K

Market cap

$183.27M

Shares out

27.6M

P/E

—

P/S

5.35

P/B

4.05

P/FCF

—

ROE

-127.6%

ROA

-45.9%

Debt/Equity

0.50

Div yield

0.00%

As of Oct 23, 2026

• Cfo departureJul 27, 2026

  Mr. Kelly and the Company mutually agreed to Mr. Kelly's promotion from the role of Chief Financial Officer to Chief Operating Officer, and this transition was not the result of any disagreement with the Company or its Board relating to the Company's operations, policies or practices or any issues regarding its accounting policies or practices.

• Clinical trial resultsJul 1, 2026

  The Company announced PBGENE-HBV clinical highlights from its ELIMINATE-B study for chronic hepatitis B, including liver biopsy data demonstrated that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts.

• Credit facilityJun 16, 2026

  On June 10, 2026, Precision BioSciences, Inc. (the "Company") and Banc of California (the "Lender") entered into a First Amendment to Amended and Restated Loan and Security Agreement (the "First Amendment"). The First Amendment amended the Amended and Restated Loan and Security Agreement, dated July 31, 2024, between the Company and Lender.

• Clinical trial resultsMay 27, 2026

  New clinical data demonstrate that PBGENE-HBV achieved pgRNA loss in 100% of patients (n=6) with detectable pgRNA at baseline. Complete loss of detectable blood pgRNA directly corresponded to undetectable pgRNA in post-treatment liver biopsy, further supporting pgRNA as the appropriate clinical biomarker for assessing PBGENE-HBV effect on cccDNA in the liver.

• Charter amendmentMay 26, 2026

  At the Meeting, the Company's stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation (the '2026 Amendment') to provide for the exculpation of certain officers of the Company as permitted by Delaware law.

Days to cover

8.8

Short interest

2.51M

Avg volume

285.28K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• CPTx appoints Matt Kane as Chief Financial Officer
  neutralGlobeNewswire Inc.· Sep 8, 2026
• Gene Editing Therapeutics: Transforming Biopharmaceuticals with 12.5% CAGR Growth Forecast
  positiveGlobeNewswire Inc.· Jul 3, 2026
• Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape
  positiveGlobeNewswire Inc.· May 26, 2026
• Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment Trends
  positiveGlobeNewswire Inc.· Jan 22, 2026
• CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain
  positiveGlobeNewswire Inc.· Mar 5, 2025